A Study of CM326 in Subjects With Moderate to Severe Asthma

Summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week treatment period, and a 12-week safety follow-up period.

Timeline

Start

2023-05-18

Primary completion

2025-01

Completion

2025-01

Drugs

Indications